Bristol-Myers Squibb Company is a large biopharmaceutical company that develops and sells medicines. Its filings show it lobbies Congress on health-care payment and access issues, including Medicare and Medicaid payment reform, implementation of the Inflation Reduction Act of 2022, the 340B drug discount program, biosimilars reimbursement, pharmacy benefit manager reform, and supply chain concerns. It has reported using Todd Strategy Group for advocacy.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DANIEL M TODD
The latest disclosures for this client.
TODD STRATEGY GROUP
Q2TODD STRATEGY GROUP
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
TODD STRATEGY GROUP
ERIC BERGREN
TODD STRATEGY GROUP
KATHERINE FLEMING COTTON
TODD STRATEGY GROUP
PAUL EDATTEL
TODD STRATEGY GROUP
TED LEHMAN
TODD STRATEGY GROUP
JEFF LUCAS
TODD STRATEGY GROUP
KIMBERLY LINTHICUM
TODD STRATEGY GROUP
TODD STRATEGY GROUP
Q4TODD STRATEGY GROUP
Q3TODD STRATEGY GROUP
Q2TODD STRATEGY GROUP
Q1